AOD-9604 is a modified 16-amino acid C-terminal fragment of human growth hormone (Tyr-hGH 177–191) stabilized by a Cys7–Cys14 disulfide loop, studied in lipolysis and anti-lipogenesis models independent of IGF-1 proliferation.
Scientific Profile & Research Key Points: AOD-9604
AOD-9604 is a modified 16-amino acid C-terminal fragment of human growth hormone (Tyr-hGH 177–191) stabilized by a Cys7–Cys14 disulfide loop, studied in lipolysis and anti-lipogenesis models independent of IGF-1 proliferation.
Active Batch Release Specifications (Lot SL-2026-106)
Analytical release verification for current AOD-9604 (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-106 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Pre-solubilize in 0.1–0.2 mL sterile 0.6% Acetic Acid, then dilute with sterile Bacteriostatic Water
Temperature & Stability
Store lyophilized vial at -20°C; refrigerate reconstituted solution at 2°C–8°C and avoid alkaline pH (>7.5) to prevent gelation.
AOD-9604 — Technical Questions & Answers
What is the molar concentration when reconstituting AOD-9604 (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of AOD-9604 (MW 1815.08 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 1.38 mM (1,377 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does AOD-9604's counterion stoichiometry affect assay mass calculations?
AOD-9604 (CAS 221231-10-3, formula C78H123N23O23S2) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify AOD-9604 Lot SL-2026-106 and what pathway does it target?
Lot SL-2026-106 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 1815.08 g/mol. In preclinical literature, AOD-9604 targets β3-adrenergic lipolytic signaling pathways (non-IGF-1 axis) (Ng F.M. et al., Horm Res (2000) — Metabolic actions of human growth hormone C-terminal fragment 177–191 (PMID: 11146367)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.
Related Metabolic & Incretin Research Compounds
View category →